Boudrant G, Mangin P, Feuillu B, Peiffert D, Cormier L
Service d'urologie, CHRU Brabois, allée du Morvan, 54500 Vandoeuvre-Les-Nancy, France.
Prog Urol. 2009 Sep;19(8):542-52. doi: 10.1016/j.purol.2009.01.015. Epub 2009 Apr 23.
The treatment of prostate cancer using high intensity focused ultrasound (HIFU) is considered to be mini-invasive and normally has a low rate of morbidity. The aim of this study was to evaluate the quality of life of patients treated with HIFU.
Fifty consecutive patients whose first-line treatment was with HIFU for localized cancer of the prostate between 2003 and 2005 received the "UCLA/RAND PCI" quality of life questionnaire at preoperative stage and one year after treatment. The scores for postoperative quality of life were compared to preoperative scores and to a test population who did not have prostate cancer.
Eighty percent of patients answered both questionnaires. 72.5% of the patients were "satisfied" or "very satisfied", 2.5% were "very dissatisfied" and 25% had no opinion. The general quality of life scores (SF-36) did not show any significant differences before and after treatment. Alterations and discomfort concerning sexual and urinary functions were statistically significant. For the digestive function, there was no difference before and after treatment; however, an increase in discomfort felt was statistically significant.
The treatment of prostate cancer using HIFU is accepted well by the patient, quality of life is preserved one year later. There is significant degradation of the sexual function and more moderately of the urinary function.
高强度聚焦超声（HIFU）治疗前列腺癌被认为是微创的，且通常发病率较低。本研究的目的是评估接受HIFU治疗的患者的生活质量。
2003年至2005年间，50例一线治疗采用HIFU治疗局限性前列腺癌的连续患者在术前及治疗后一年接受了“加州大学洛杉矶分校/兰德前列腺癌指数（UCLA/RAND PCI）”生活质量问卷。将术后生活质量评分与术前评分以及未患前列腺癌的测试人群进行比较。
80%的患者回答了两份问卷。72.5%的患者“满意”或“非常满意”，2.5%的患者“非常不满意”，25%的患者无意见。总体生活质量评分（SF - 36）在治疗前后未显示出任何显著差异。性功能和排尿功能方面的改变及不适在统计学上具有显著意义。消化功能在治疗前后无差异；然而，感觉不适的增加在统计学上具有显著意义。
患者对使用HIFU治疗前列腺癌的接受度良好，一年后生活质量得以保留。性功能有显著下降，排尿功能下降程度相对较小。
